In 2020, the world's top 10 anticancer drugs

Source: bioprospecting 2016-4-15 according to the statistics of the World Health Organization (who), about 8.2 million people die of cancer every year, which is expected to account for 13% of the global death toll; meanwhile, who predicts that cancer cases will increase by 70% in the next 20 years Fortunately, many pharmaceutical and biotech companies are paying attention to this need A 2016 statistical report of statista forecasts the top ten anti-cancer drugs in the world in 2020 The ranking is based on the benefits brought by the drugs, as follows: 1 Revlimid (lenalidomide) Company: the estimated sales volume of new base in 2020: US $10.11 billion Revlimid It is approved for the treatment of multiple myeloma and mantle cell lymphoma, and also for the treatment of myelodysplastic syndrome 2 Imbruvica (ibrutinib) Co., Ltd.: $8.213 billion Imbruvica & Johnson's estimated sales in 2020: imbruvica was initially jointly developed by Johnson and pharmacyclics After that, Johnson and Johnson planned to acquire pharmacyclics with more than $17 billion in March last year, but it was successfully "married" by Albright with $21 billion Since it was approved by FDA in November 2013, its indications have been expanding In February 2014, it was approved for the treatment of chronic lymphocytic leukemia (CLL) patients who had received other therapies, and in July 2014, it was approved for the treatment of CLL patients with del 17p mutation type In March this year, imbruvica was approved by FDA for first-line treatment of CLL patients In addition, the indications of imbruvica include Waldenstrom macroglobulinemia and mantle cell lymphoma 3 Avastin (bevacizumab): Roche's estimated sales volume in 2020: US $6.733 billion Avastin It is a kind of angiogenesis inhibitor, which can block tumor by inhibiting the action of vascular endothelial growth factor and inhibit tumor diffusion in vivo It is used to treat metastatic colorectal cancer, non squamous non-small cell lung cancer, glioblastoma, metastatic renal cell cancer, cervical cancer, platinum resistant recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer Avastin sold 6.6 billion francs last year 4 Opdivo (nivolumab) Company: the estimated sales volume of BMS in 2020 is US $6.201 billion Opdivo is a PD-1 inhibitor, which brought us $942 million in revenue to BMS in 2015 In addition to the indications of melanoma and lung cancer, good news has come recently Opdivo has become the first PD-1 antibody approved in Europe for the treatment of renal cell carcinoma At the same time, the EU officially accepts the application of opdivo for the treatment of classic Hodgkin's lymphoma, marking the first time that PD-1 / PD-L1 immunotherapy has entered the field of blood tumor regulation 5 Xtandi (enzalutamide) Co., Ltd.: $5.7 billion estimated sales volume of medivation & astras in 2020 xtandi is an androgen receptor inhibitor for the treatment of metastatic resistant prostate cancer 6 Rituximab: Roche's estimated sales in 2020: US $5.407 billion Rituxan is approved for the treatment of non Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangitis (GPA), and microscopical polyangitis (MPA) Rituxan is one of the top 10 drugs sold in the world in 2015, with sales of US $7.5 billion, and the patent expires in 2018 7 Ibrance (palbociclib) Company: Pfizer's estimated sales in 2020: US $4722 million Ibrance is an oral cyclin dependent kinase (CDKs) 4 and 6 inhibitor CDKs 4 and 6 are key regulators of cell cycle, which can trigger cell cycle progression In February last year, Pfizer announced today that the U.S Food and Drug Administration (FDA) has accelerated the approval of ibrance ® (palbociclib) in combination with Femara (Novartis' oncology drug) as an initial regimen based on endocrine therapy for ER + / HER2 - postmenopausal advanced breast cancer This year, the FDA expanded the indications of ibrance and approved the combination of AstraZeneca oncology drug faslodex for the treatment of advanced or metastatic breast cancer women with hormone receptor positive (HR +, HER2 -) and human epidermal growth factor receptor 2 negative (HER2 -) after endocrine therapy 8 Perjeta (pertuzumab): Roche's estimated sales in 2020: US $4.669 billion The sales of HER2 positive breast cancer drug increased by 61% last year, bringing Roche 1.4 billion francs of revenue Through combination drugs, perjeta also helped Herceptin's sales, which rose 10% last year 9 Herceptin (trastuzumab): Roche's estimated sales in 2020: US $4.573 billion Herceptin is used to treat early breast cancer, metastatic breast cancer and gastric cancer, and the US patent will expire in 2019; sales in 2015 are 6.5 billion francs 10 Keytruda (pembrolizumab) Co., Ltd.: the estimated sales volume of MSD in 2020: US $3.56 billion keytruda is another PD-1 antibody The current indications are unresectable or metastatic melanoma and metastatic non-small cell lung cancer In 2015, the annual sales reached 566 million US dollars On April 13, MSD announced that FDA has accepted keytruda's license application for complementary biological products for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck during or after chemotherapy of platinum drugs, and granted priority review qualification at the same time The scheduled approval period is August 9, 2016.